(CVRX) CVRx - Overview
Stock: Neuromodulation, Device, Heart Failure, Baroreceptors
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 94.3% |
| Relative Tail Risk | -26.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.34 |
| Alpha | -81.64 |
| Character TTM | |
|---|---|
| Beta | 1.785 |
| Beta Downside | 1.242 |
| Drawdowns 3y | |
|---|---|
| Max DD | 85.61% |
| CAGR/Max DD | -0.33 |
Description: CVRX CVRx January 02, 2026
CVRx, Inc. (NASDAQ:CVRX) is a commercial-stage medical-device firm that designs, manufactures, and markets neuromodulation therapies for cardiovascular disease, primarily heart-failure patients, across the United States, Germany, and other international markets. Its flagship product, the Barostim™ system, delivers calibrated electrical pulses to baroreceptors to improve heart-failure symptoms and is sold via a hybrid model of direct sales, regional agents, and independent distributors. Founded in 2000, the company is headquartered in Minneapolis, Minnesota, and trades as a common-stock health-care equipment issuer.
Key recent metrics (Q2 2024): revenue of $10.3 million, cash and cash equivalents of $71 million, and a net loss of $23 million, reflecting ongoing R&D and commercialization spend. The heart-failure market is expanding at a ~5% CAGR, driven by an aging population and rising prevalence of reduced-ejection-fraction HF; Medicare reimbursement for Barostim™ has been approved in several jurisdictions, supporting revenue scalability. The broader neuromodulation sector is experiencing a 12% annual growth rate, underpinned by advances in implantable-device technology and increasing payer acceptance.
For a deeper, data-driven perspective, you may find ValueRay’s analyst dashboard useful for tracking CVRx’s financial trends and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -52.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -3.33 > 1.0 |
| NWC/Revenue: 172.7% < 20% (prev 239.0%; Δ -66.25% < -1%) |
| CFO/TA -0.35 > 3% & CFO -38.4m > Net Income -52.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (26.2m) vs 12m ago 14.86% < -2% |
| Gross Margin: 84.97% > 18% (prev 0.84%; Δ 8414 % > 0.5%) |
| Asset Turnover: 46.84% > 50% (prev 37.01%; Δ 9.82% > 0%) |
| Interest Coverage Ratio: -7.79 > 6 (EBITDA TTM -45.4m / Interest Expense TTM 5.93m) |
Altman Z'' -15.00
| A: 0.87 (Total Current Assets 107.9m - Total Current Liabilities 11.2m) / Total Assets 111.3m |
| B: -5.20 (Retained Earnings -578.7m / Total Assets 111.3m) |
| C: -0.39 (EBIT TTM -46.2m / Avg Total Assets 119.5m) |
| D: -9.15 (Book Value of Equity -578.7m / Total Liabilities 63.3m) |
| Altman-Z'' Score: -23.45 = D |
Beneish M -3.14
| DSRI: 0.77 (Receivables 8.21m/9.03m, Revenue 56.0m/47.3m) |
| GMI: 0.98 (GM 84.97% / 83.59%) |
| AQI: 1.15 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.18 (Revenue 56.0m / 47.3m) |
| TATA: -0.12 (NI -52.0m - CFO -38.4m) / TA 111.3m) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of CVRX shares?
Over the past week, the price has changed by -7.69%, over one month by -9.26%, over three months by -32.82% and over the past year by -54.98%.
Is CVRX a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CVRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11 | 58% |
| Analysts Target Price | 11 | 58% |
| ValueRay Target Price | 6.5 | -6.2% |
CVRX Fundamental Data Overview February 02, 2026
P/B = 3.7307
Revenue TTM = 56.0m USD
EBIT TTM = -46.2m USD
EBITDA TTM = -45.4m USD
Long Term Debt = 49.5m USD (from longTermDebt, last quarter)
Short Term Debt = 282.0k USD (from shortTermDebt, last fiscal year)
Debt = 50.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -34.9m USD (from netDebt column, last quarter)
Enterprise Value = 144.6m USD (179.5m + Debt 50.2m - CCE 85.1m)
Interest Coverage Ratio = -7.79 (Ebit TTM -46.2m / Interest Expense TTM 5.93m)
EV/FCF = -3.71x (Enterprise Value 144.6m / FCF TTM -39.0m)
FCF Yield = -26.96% (FCF TTM -39.0m / Enterprise Value 144.6m)
FCF Margin = -69.65% (FCF TTM -39.0m / Revenue TTM 56.0m)
Net Margin = -92.95% (Net Income TTM -52.0m / Revenue TTM 56.0m)
Gross Margin = 84.97% ((Revenue TTM 56.0m - Cost of Revenue TTM 8.41m) / Revenue TTM)
Gross Margin QoQ = 86.81% (prev 84.26%)
Tobins Q-Ratio = 1.30 (Enterprise Value 144.6m / Total Assets 111.3m)
Interest Expense / Debt = 2.95% (Interest Expense 1.48m / Debt 50.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -36.5m (EBIT -46.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.62 (Total Current Assets 107.9m / Total Current Liabilities 11.2m)
Debt / Equity = 1.04 (Debt 50.2m / totalStockholderEquity, last quarter 48.1m)
Debt / EBITDA = 0.77 (negative EBITDA) (Net Debt -34.9m / EBITDA -45.4m)
Debt / FCF = 0.90 (negative FCF - burning cash) (Net Debt -34.9m / FCF TTM -39.0m)
Total Stockholder Equity = 61.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.53% (Net Income -52.0m / Total Assets 111.3m)
RoE = -84.45% (Net Income TTM -52.0m / Total Stockholder Equity 61.6m)
RoCE = -41.58% (EBIT -46.2m / Capital Employed (Equity 61.6m + L.T.Debt 49.5m))
RoIC = -32.87% (negative operating profit) (NOPAT -36.5m / Invested Capital 111.0m)
WACC = 10.27% (E(179.5m)/V(229.7m) * Re(12.49%) + D(50.2m)/V(229.7m) * Rd(2.95%) * (1-Tc(0.21)))
Discount Rate = 12.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.09%
Fair Price DCF = unknown (Cash Flow -39.0m)
EPS Correlation: 25.18 | EPS CAGR: 17.21% | SUE: 2.43 | # QB: 1
Revenue Correlation: 91.64 | Revenue CAGR: 44.88% | SUE: 1.42 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.50 | Chg30d=+0.002 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.91 | Chg30d=-0.006 | Revisions Net=-1 | Growth EPS=+5.6% | Growth Revenue=+15.6%